Stay updated on NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page.

Latest updates to the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page
- CheckyesterdayChange DetectedNotice about government funding status was removed from the page. The removed notice previously warned that information may not be up to date and directed users to cc.nih.gov and opm.gov for status updates.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedResults for the study were posted, including progression-free survival, objective response rate, and safety data. The study record dates were updated to reflect the availability of results.SummaryDifference0.4%

- Check30 days agoChange DetectedAdditions substantially update the study description with precise dosing, duration, endpoints, and reporting dates; deletions remove the older, shorter phrasing. Overall, the page content has been significantly expanded and clarified.SummaryDifference8%

- Check44 days agoChange DetectedAdditions introduce a government funding notice and confirm the NIH Clinical Center is open, plus a v3.2.0 revision; deletions remove v3.1.0.SummaryDifference3%

- Check52 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now displays Revision: v3.0.2, replacing the previous v3.0.1. Additionally, the Back to Top link was removed, a minor navigational change with little impact on core content.SummaryDifference0.2%

Stay in the know with updates to NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NIVO-IPI-TAXANE in Metastatic NSCLC Clinical Trial page.